drugset / Trial / NCT03765502

A Study Comparing User Experience of Different Delivery Devices for Glucagon

NCT03765502

Phase 1 Completed 99 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelOther

Summary

The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will last approximately 17 days for Trained Users and Participants with Diabetes (PWD). Part B will last approximately nine (9) days for Untrained Users. Each part will be separated by approximately 7 days.

Timeline

Start
2018-11-19
Primary completion
2019-01-03
Completion
2019-01-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glucagon Peptide Intramuscular

Indications

No indication recorded.